P/B
5
Candel Therapeutics
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
$626.7M
Market Cap • 10/16/2026
2003
(23 years)
Founded
2021
(5 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
1,6
EPS
—
Market Cap
Market Cap
626,7M
EV
474,6M
EV/Revenue
0
EV/EBITDA
-6,7
EV/EBIT
-6,6
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-18,7%
Total Yield
-18,7%
Payout
0%
Retained Earnings
-278,2M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
191,3%
Capex/OCF
-2,3%
SBC/OCF
—
% PPE
1,7%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-100%
CAGR Op. Income 5Y
30,8%
CAGR Net Income 5Y
20,7%
CAGR EPS 5Y
-13,8%
CAGR OCF 5Y
30,1%
Leverage
N.D./EBITDA
2,1
Debt/Equity
0%
Current Ratio
16,1
Quick Ratio
15,9
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!